ChEMBL ligand: CHEMBL593 (Delavirdina, Delavirdine, U-90152)
ABCG2/ATP-binding cassette sub-family G member 2 in Human [ChEMBL: CHEMBL5393] [GtoPdb: 792] [UniProtKB: Q9UNQ0] There should be some charts here, you may need to enable JavaScript!
Beta-lactamase AmpC in Escherichia coli [ChEMBL: CHEMBL2026] [UniProtKB: P00811] There should be some charts here, you may need to enable JavaScript!
Human immunodeficiency virus type 1 integrase in Human immunodeficiency virus 1 [ChEMBL: CHEMBL3471] [UniProtKB: Q7ZJM1] There should be some charts here, you may need to enable JavaScript!
Human immunodeficiency virus type 1 protease in Human immunodeficiency virus 1 [ChEMBL: CHEMBL243] [UniProtKB: Q72874] There should be some charts here, you may need to enable JavaScript!
Human immunodeficiency virus type 1 reverse transcriptase in Human immunodeficiency virus 1 [ChEMBL: CHEMBL247] [UniProtKB: Q72547] There should be some charts here, you may need to enable JavaScript!
Malate dehydrogenase cytoplasmic in Human [ChEMBL: CHEMBL3560] [UniProtKB: P40925] There should be some charts here, you may need to enable JavaScript!
Plasmodium falciparum [ChEMBL: CHEMBL364] There should be some charts here, you may need to enable JavaScript!
Plasmodium yoelii yoelii [ChEMBL: CHEMBL612328] There should be some charts here, you may need to enable JavaScript!

DB	Assay description	Assay Type	Standard value	Standard parameter	Original value	Original units	Original parameter	Reference
ABCG2/ATP-binding cassette sub-family G member 2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5393] [GtoPdb: 792] [UniProtKB: Q9UNQ0]
ChEMBL	Inhibition of human ABCG2 expressed in dog MDCK-II-BCRP cells mediated pheophorbide A efflux preincubated with PhA followed by compound addition and measured after 60 mins by flow cytometry	B	4.73	pIC50	18700	nM	IC50	Eur J Med Chem (2022) 237: 114346-114346 [PMID:35483322]
Beta-lactamase AmpC in Escherichia coli (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2026] [UniProtKB: P00811]
ChEMBL	Compound was tested for the inhibition of beta-lactamase	B	4.05	pIC50	90000	nM	IC50	J Med Chem (2003) 46: 4477-4486 [PMID:14521410]
Human immunodeficiency virus type 1 integrase in Human immunodeficiency virus 1 (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3471] [UniProtKB: Q7ZJM1]
ChEMBL	Inhibition of HIV1 integrase	B	4	pIC50	>100000	nM	IC50	Bioorg Med Chem (2016) 24: 5007-5016 [PMID:27658796]
Human immunodeficiency virus type 1 protease in Human immunodeficiency virus 1 (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL243] [UniProtKB: Q72874]
ChEMBL	Inhibition of HIV-1 protease	B	8.89	pIC50	1.3	nM	IC50	RSC Med Chem (2024) 15: 788-808 [PMID:38516587]
Human immunodeficiency virus type 1 reverse transcriptase in Human immunodeficiency virus 1 (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL247] [UniProtKB: Q72547]
ChEMBL	Inhibitory activity against P236L mutant HIV-1 reverse transcriptase	B	4.74	pIC50	18000	nM	IC50	J Med Chem (1998) 41: 1357-1360 [PMID:9554867]
ChEMBL	Inhibition of Reverse transcriptase (P236L) using poly(rA)600:oligo(dT)10 as template primer.	B	4.74	pIC50	18000	nM	IC50	J Med Chem (1999) 42: 4140-4149 [PMID:10514284]
ChEMBL	Inhibition of Reverse transcriptase (Y181C) using poly(rA)600:oligo(dT)10 as template primer.	B	5.08	pIC50	8320	nM	IC50	J Med Chem (1999) 42: 4140-4149 [PMID:10514284]
ChEMBL	Inhibition of wild type recombinant HIV1 reverse transcriptase Y181C mutant using poly(rA)-oligo(dT) as template/primer	B	5.08	pIC50	8300	nM	IC50	J Med Chem (2019) 62: 4851-4883 [PMID:30516990]
ChEMBL	Inhibitory activity against Y181C mutant HIV-1 reverse transcriptase	B	5.08	pIC50	8300	nM	IC50	J Med Chem (1998) 41: 1357-1360 [PMID:9554867]
ChEMBL	Inhibitory activity against HIV-1 reverse transcriptase (P236L)	B	5.18	pIC50	6660	nM	IC50	J Med Chem (1998) 41: 3793-3803 [PMID:9748354]
ChEMBL	Inhibition of recombinant reverse transcriptase (RT) in cell-free Quan-T-RT assay system	B	5.82	pIC50	1500	nM	IC50	Bioorg Med Chem Lett (1999) 9: 3411-3416 [PMID:10617082]
ChEMBL	Inhibitory activity against recombinant HIV-1 reverse transcriptase (rRT)	B	5.82	pIC50	1500	nM	IC50	Bioorg Med Chem Lett (1999) 9: 2721-2726 [PMID:10509923]
ChEMBL	Inhibition of purified recombinant HIV-1 reverse transcriptase	B	5.82	pIC50	1500	nM	IC50	Bioorg Med Chem Lett (1999) 9: 1593-1598 [PMID:10386942]
ChEMBL	Compound was evaluated for its inhibitory activity against recombinant HIV-1 Reverse transcriptase using cell free RT inhibition assay	B	5.82	pIC50	1500	nM	IC50	Bioorg Med Chem Lett (2000) 10: 2071-2074 [PMID:10999473]
ChEMBL	Inhibition of HIV1 wild type reverse transcriptase using poly rC.dG and [3H]dGTP as substrate	B	5.92	pIC50	1200	nM	IC50	Medchemcomm (2013) 4: 741-748
ChEMBL	Dose required to inhibit the HIV-1 Reverse transcriptase activity by 50%	B	5.96	pIC50	1100	nM	IC50	J Med Chem (2002) 45: 1567-1576 [PMID:11931611]
ChEMBL	In vitro for inhibition of HIV-1 reverse transcriptase.	B	5.96	pIC50	1100	nM	IC50	J Med Chem (1996) 39: 5267-5275 [PMID:8978855]
ChEMBL	In vitro inhibition of HIV-1 reverse transcriptase	B	5.96	pIC50	1100	nM	IC50	J Med Chem (1993) 36: 1505-1508 [PMID:7684450]
ChEMBL	Inhibition of HIV-1 reverse transcriptase.	B	6.37	pIC50	422	nM	IC50	J Med Chem (2000) 43: 2019-2030 [PMID:10821714]
ChEMBL	Inhibition of wild type recombinant HIV1 reverse transcriptase using poly(rA)-oligo(dT) as template/primer	B	6.59	pIC50	260	nM	IC50	J Med Chem (2019) 62: 4851-4883 [PMID:30516990]
ChEMBL	Inhibition of Reverse transcriptase (Wild Type) with poly(rA)600:oligo(dT)10 template primer	B	6.59	pIC50	260	nM	IC50	J Med Chem (1999) 42: 4140-4149 [PMID:10514284]
ChEMBL	Inhibitory activity against wild type HIV-1 reverse transcriptase (WT-RT)	B	6.59	pIC50	260	nM	IC50	J Med Chem (1998) 41: 1357-1360 [PMID:9554867]
ChEMBL	Inhibitory activity against HIV-1 reverse transcriptase (wild type)	B	6.77	pIC50	170	nM	IC50	J Med Chem (1998) 41: 3793-3803 [PMID:9748354]
ChEMBL	HIV-1 reverse transcriptase inhibitory activity against Asn103 mutant using (poly)rC600*(oligo)dGT as template primer.	B	7.25	pIC50	56	nM	IC50	J Med Chem (1999) 42: 4150-4160 [PMID:10514285]
ChEMBL	Inhibition of recombinant HIV1 non-nucleoside reverse transcriptase	B	7.44	pIC50	36	nM	IC50	Bioorg Med Chem (2016) 24: 5007-5016 [PMID:27658796]
ChEMBL	Inhibitory concentration against wild-type reverse transcriptase of HIV-1	B	7.68	pIC50	21	nM	IC50	J Med Chem (2004) 47: 1175-1182 [PMID:14971897]
ChEMBL	HIV-1 reverse transcriptase inhibitory activity against Cys181 mutant using (poly)rC600*(oligo)dGT as template primer.	B	8.05	pIC50	9	nM	IC50	J Med Chem (1999) 42: 4150-4160 [PMID:10514285]
ChEMBL	HIV-1 reverse transcriptase inhibitory activity against Ile 100 mutant using (poly)rC600*(oligo)dGT as template primer.	B	8.05	pIC50	9	nM	IC50	J Med Chem (1999) 42: 4150-4160 [PMID:10514285]
ChEMBL	HIV-1 reverse transcriptase inhibitory activity against Wild Type Reverse transcriptase using (poly)rC600*(oligo)dGT as template primer.	B	8.1	pIC50	8	nM	IC50	J Med Chem (1999) 42: 4150-4160 [PMID:10514285]
ChEMBL	Inhibition of HIV1 RES056 reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured at 5 days post infection by MTT assay	B	4.64	pEC50	>23000	nM	EC50	Bioorg Med Chem (2017) 25: 2491-2497 [PMID:28314514]
ChEMBL	Inhibition of HIV RT K103N/Y181C mutant by cell based assay	B	5	pEC50	>10000	nM	EC50	Eur J Med Chem (2013) 65: 134-143 [PMID:23707918]
ChEMBL	Inhibition of HIV-1 reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured at 5 days post infection by MTT assay	B	7.12	pEC50	76	nM	EC50	Bioorg Med Chem (2017) 25: 2491-2497 [PMID:28314514]
Malate dehydrogenase cytoplasmic in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3560] [UniProtKB: P40925]
ChEMBL	Inhibition of malate dehydrogenase (MDH)	B	4.07	pIC50	85000	nM	IC50	J Med Chem (2003) 46: 4477-4486 [PMID:14521410]
Plasmodium falciparum (target type: ORGANISM) [ChEMBL: CHEMBL364]
ChEMBL	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 infected in human O positive erythrocyte assessed as reduction in parasitemia after 72 hrs	F	4.19	pIC50	64000	nM	IC50	Bioorg Med Chem (2014) 22: 5241-5248 [PMID:25199582]
Plasmodium yoelii yoelii (target type: ORGANISM) [ChEMBL: CHEMBL612328]
ChEMBL	Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs	F	9.07	pIC50	0.85	nM	IC50	Antimicrob Agents Chemother (2008) 52: 1215-1220 [PMID:18212104]
ChEMBL	Antimalarial activity against liver stages of Plasmodium yoelii yoelii	F	9.07	pIC50	0.85	nM	IC50	J Med Chem (2012) 55: 995-1012 [PMID:22122518]

ChEMBL data shown on this page come from version 34:

Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]